Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FKBP1A | P62942 | 7/20 | 0.50 |
| ▸ | KLK7 | P49862 | 1/20 | 0.48 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.47 |
| ▸ | NPC1 | O15118 | 2/20 | 0.47 |
| ▸ | RAB9A | P51151 | 2/20 | 0.47 |
| ▸ | PARP1 | P09874 | 1/20 | 0.47 |
| ▸ | HTT | P42858 | 1/20 | 0.47 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.46 |
| ▸ | TMEM97 | Q5BJF2 | 1/20 | 0.45 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.45 |
| ▸ | PREP | P48147 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1488503 | 1.00 | FKBP1A (0.50) | FKBP1AKLK7SMN1; SMN2NPC1RAB9A | |
| SCHEMBL1488666 | 1.00 | FKBP1A (0.50) | FKBP1AKLK7SMN1; SMN2NPC1RAB9A | |
| SCHEMBL3114029 | 0.90 | SMN1; SMN2 (0.52) | FKBP1ASMN1; SMN2NPC1RAB9ACYP2C19 | |
| SCHEMBL3098746 | 0.90 | SMN1; SMN2 (0.52) | FKBP1ASMN1; SMN2NPC1RAB9ACYP2C19 | |
| SCHEMBL2721261 | 0.90 | SMN1; SMN2 (0.52) | FKBP1ASMN1; SMN2NPC1RAB9ACYP2C19 | |
| SCHEMBL18089695 | 0.88 | SMN1; SMN2 (0.50) | KLK7SMN1; SMN2NPC1RAB9APARP1 | |
| SCHEMBL3835409 | 0.86 | ACE2 (0.49) | FKBP1ASMN1; SMN2NPC1RAB9ACYP2C19 | |
| SCHEMBL31566928 | 0.85 | SMN1; SMN2 (0.47) | KLK7SMN1; SMN2NPC1RAB9APARP1 | |
| SCHEMBL31566548 | 0.85 | SMN1; SMN2 (0.47) | KLK7SMN1; SMN2NPC1RAB9APARP1 | |
| SCHEMBL4974458 | 0.83 | HSD17B10 (0.55) | FKBP1AKLK7SMN1; SMN2NPC1RAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250100966-A1 | MEK INHIBITORS AND METHODS OF THEIR USE | EXELIXIS INC (US) | 2025-03-27 | — | — | US | disclosed |
| US-11597699-B2 | MEK inhibitors and methods of their use | EXELIXIS, INC. (US) | 2023-03-07 | — | — | US | disclosed |
| US-10407403-B2 | Preparation method of cobimetinib | SUZHOU MIRACPHARMA TECHNOLOGY CO., LTD. (CN) | 2019-09-10 | — | — | US | disclosed |
| EP-2101759-B1 | METHODS OF USING MEK INHIBITORS | EXELIXIS INC (US) | 2018-10-10 | — | — | EP | disclosed |
| CN-106045969-A | Synthesis method of cobimetinib | 湖南欧亚生物有限公司 | 2016-10-26 | — | — | CN | disclosed |
| US-20140275527-A1 | Azetidines as MEK Inhibitors for the Treatment of Proliferative Diseases | EXELIXIS, INC. (US) | 2014-09-18 | — | — | US | disclosed |
| US-20140275527-A1 | Azetidines as MEK Inhibitors for the Treatment of Proliferative Diseases | EXELIXIS, INC. (US) | 2014-09-18 | — | — | US | disclosed |
| US-20110263558-A1 | Azetidines as MEK Inhibitors for the Treatment of Proliferative Diseases | EXELIXIS, INC. (US) | 2011-10-27 | — | — | US | disclosed |
| US-7999006-B2 | Anticancer agents; mitogen-activated protein kinases (MEK) | EXELIXIS, INC. (US) | 2011-08-16 | — | — | US | disclosed |
| EP-1934174-B1 | AZETIDINES AS MEK INHIBITORS FOR THE TREATMENT OF PROLIFERATIVE DISEASES | EXELIXIS INC (US) | 2011-04-06 | — | — | EP | disclosed |
| US-7915250-B2 | Azetidines as MEK inhibitors for the treatment of proliferative diseases | EXELIXIS, INC. (US) | 2011-03-29 | — | — | US | disclosed |
| US-20100249096-A1 | anticarcinogenic agent; 1-({4-[(2-fluoro-4-iodophenyl)amino]-3-thienyl}carbonyl)azetidin-3-amine | EXELIXIS, INC. (US) | 2010-09-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10407403-B2 | Preparation method of cobimetinib | TET2, ABL1, CBLC | FKBP1A 4756/4885KLK7 4546/4885SMN1; SMN2 3451/4885 |
| US-20100249096-A1 | anticarcinogenic agent; 1-({4-[(2-fluoro-4-iodophenyl)amino]-3-thienyl}carbonyl)azetidin-3-amine | NRAS, BRAF, KRAS | FKBP1A 4706/4885KLK7 2301/4885SMN1; SMN2 3758/4885 |
| US-20110263558-A1 | Azetidines as MEK Inhibitors for the Treatment of Proliferative Diseases | NRAS, BRAF, KRAS | FKBP1A 2857/4885KLK7 2699/4885SMN1; SMN2 2697/4885 |
| US-20250100966-A1 | MEK INHIBITORS AND METHODS OF THEIR USE | BRAF, NRAS, KRAS | FKBP1A 3736/4885KLK7 1525/4885SMN1; SMN2 3747/4885 |
| US-20140275527-A1 | Azetidines as MEK Inhibitors for the Treatment of Proliferative Diseases | NRAS, BRAF, KRAS | FKBP1A 2857/4885KLK7 2699/4885SMN1; SMN2 2697/4885 |
| US-11597699-B2 | MEK inhibitors and methods of their use | BRAF, NRAS, MAP3K20 | FKBP1A 3583/4885KLK7 1174/4885SMN1; SMN2 3755/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.